Department of Dermatology, Radboud University Nijmegen Medical Centre, NL-6500 HB Nijmegen, the Netherlands.
Acta Derm Venereol. 2022 Feb 28;102:adv00660. doi: 10.2340/actadv.v101.981.
This study is a retrospective analysis using data collected from the Adelphi Paediatric Psoriasis Disease-Specific Programme cross-sectional survey. Despite being treated for their psoriasis, a substantial proportion of paediatric patients presented with moderate (18.3%) or severe (1.3%) disease at sampling; 42.9% and 92.0% had a body surface area (BSA) of >10%, and 38.8% and 100.0% had a Psoriasis Area Severity Index (PASI) score >10, respectively. Overall, 69.9% of patients had only ever been treated with a topical therapy for their psoriasis. For patients with moderate or severe disease at sampling, 16.3% and 14.4% were currently receiving conventional systemics or biologic therapy, respectively. There is a clinical unmet need in this paediatric population; a considerable percentage of patients still experienced moderate or severe disease and persistent psoriasis symptoms, with numerous body areas affected. A significant proportion of patients were undertreated, which may explain the high burden of disease observed.
本研究采用 Adelphi Paediatric Psoriasis Disease-Specific Programme 横断面调查收集的数据进行回顾性分析。尽管接受了银屑病治疗,但在采样时仍有相当比例的儿科患者病情中度(18.3%)或重度(1.3%);42.9%和 92.0%的患者体表面积(BSA)>10%,38.8%和 100.0%的患者银屑病面积和严重程度指数(PASI)评分>10。总体而言,69.9%的患者仅接受过外用药物治疗。对于采样时病情中度或重度的患者,分别有 16.3%和 14.4%的患者目前正在接受传统的系统治疗或生物治疗。在这一儿科人群中存在临床未满足的需求;相当比例的患者仍患有中度或重度疾病,且存在持续的银屑病症状,多个身体部位受到影响。相当一部分患者治疗不足,这可能解释了观察到的高疾病负担。